Murphy Anderson Represents Pfizer Whistleblower in $2.3 Billion False Claims Act Settlement

September 2, 2009

Today, Pfizer, the United States Department of Justice and the Attorneys General of many of the States announced a settlement of $2.3 billion, including resolution of multiple False Claims Act qui tam actions alleging violations of the False Claims Act related to Pfizer's provision of prescription pharmaceuticals to various government programs, including Medicare and Medicaid.

The settlement is part of an overall public-private partnership between False Claims Act qui tam whistleblower plaintiffs, like Murphy Anderson client, Glenn DeMott of Columbus, Ohio, one of the whistleblowers whose case is part of the overall settlement — and federal and state civil and criminal prosecutors.

With this settlement, the False Claims Act shows that it is a cost- effective way to attack and prosecute False Claims Act violations,” said Ann Lugbill, who is of counsel to Murphy Anderson, an active member of the watchdog group, Taxpayers Against Fraud, and co-author of the book, False Claims Act: Whistleblower Litigation.  Murphy Anderson attorneys Mark Hanna, of Washington, DC, and Michael T. Anderson of Boston, Massachusetts, and Ann Lugbill all represented Glenn DeMott in his qui tam whistleblower litigation.

“This record-breaking settlement is appropriately announced in the 200th anniversary year of the birth of Abraham Lincoln, the father of the False Claims Act,” remarked Lugbill.